Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Federal grants	$ 789,635	$ 603,098
Operating expenses:
Research and development	1,796,015	3,140,096
General and administrative	1,554,855	2,265,806
Total operating expenses	3,350,870	5,405,902
Loss from operations	(2,561,235)	(4,802,804)
Other income (expense):
Change in fair value of convertible notes	146,479	2,767,178
Change in fair value of liability classified warrants	219,028	2,794,398
Loss on debt conversions		(1,702,642)
Interest expense, net	(1,497)	(15,021)
Other income and expense, net	5,419	7,966
Total other income, net	369,429	3,851,879
Net loss	(2,191,806)	(950,925)
Net loss attributable to noncontrolling interests	(3,941)	182
Deemed dividend related to warrants down round provision	8,309	715,579
Net loss attributable to common stockholders	$ (2,196,174)	$ (1,666,686)
Net loss per basic and diluted share:
Net loss per share attributable to common stockholders, basic and diluted	$ (2.08)	$ (14.66)
Weighted average common shares outstanding, basic and diluted	1,054,202	113,696